These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26114734)

  • 41. Defining Hemodynamic Significance of Renal Artery Stenosis: Insights From a Porcine Model of Graded Renal Artery Stenosis.
    Drieghe B; van Loon G; Decloedt A; Stuyvaert S; De Buyzere ML; Bové T; De Backer T
    Acad Radiol; 2023 Sep; 30 Suppl 1():S286-S294. PubMed ID: 37120404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The haemodynamic effects of GR 32191, a thromboxane A2 receptor antagonist, in patients with renal artery stenosis and hypertension.
    Lyons D; Fowler G; Petrie JC; Webster J
    Br J Clin Pharmacol; 1993 Sep; 36(3):271-3. PubMed ID: 9114916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Doppler flow wire evaluation of renal blood flow reserve in hypertensive patients with normal renal arteries.
    Beregi JP; Mounier-Vehier C; Devos P; Gautier C; Libersa C; McFadden EP; Carré A
    Cardiovasc Intervent Radiol; 2000; 23(5):340-6. PubMed ID: 11060362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-Energy Shockwave Therapy Improves Ischemic Kidney Microcirculation.
    Zhang X; Krier JD; Amador Carrascal C; Greenleaf JF; Ebrahimi B; Hedayat AF; Textor SC; Lerman A; Lerman LO
    J Am Soc Nephrol; 2016 Dec; 27(12):3715-3724. PubMed ID: 27297945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renoprotective effects of hepatocyte growth factor in the stenotic kidney.
    Stewart N; Chade AR
    Am J Physiol Renal Physiol; 2013 Mar; 304(6):F625-33. PubMed ID: 23269649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacoangiographic manipulation of renal collateral blood flow.
    Bookstein JJ; Walter JF; Stanley JC; Fry WJ
    Circulation; 1976 Aug; 54(2):328-34. PubMed ID: 939030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Renal course in the hypertensive patient].
    Zucchelli P; Chiarini C; Degli Esposti E; Sturani A; Santoro A; Zuccalà A
    Minerva Urol Nefrol; 1984; 36(4 Suppl):31-6. PubMed ID: 6535289
    [No Abstract]   [Full Text] [Related]  

  • 48. Hemodynamic Versus Anatomic Assessment of Symptomatic Atherosclerotic Middle Cerebral Artery Stenosis: the Relationship Between Pressure Wire Translesional Gradient and Angiographic Lesion Geometry.
    Li L; Yang B; Dmytriw AA; Wang T; Luo J; Li Y; Ma Y; Chen J; Wang Y; Gao P; Feng Y; Bai X; Zhang X; Dong J; Yang R; Jiao L; Ling F
    Front Neurol; 2021; 12():671778. PubMed ID: 34456841
    [No Abstract]   [Full Text] [Related]  

  • 49. Vasodilatory and vasoconstrictive pharmacoangiographic manipulation of renal collateral flow.
    Bookstein JJ; Ernst CB
    Radiology; 1973 Jul; 108(1):55-9. PubMed ID: 4709048
    [No Abstract]   [Full Text] [Related]  

  • 50. Fluid restitution and blood volume redistribution in anesthetized rabbits in response to vasoactive drugs.
    Anderson SM; Rich GF; Roos C; Lee LP; Lee JS
    Circulation; 1994 Jul; 90(1):509-14. PubMed ID: 8026040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypertension--pathophysiology of renal artery stenosis: clinical experimental investigations.
    Kivelitz H; Meyer W; Koehler J; Kremer K
    Angiology; 1978 Jun; 29(6):442-9. PubMed ID: 686477
    [No Abstract]   [Full Text] [Related]  

  • 52. Flosequinan and renovascular disease.
    Wood SM; Dudley CR; Devaney AM; Winearls CG
    Lancet; 1993 Jan; 341(8837):116-7. PubMed ID: 8093384
    [No Abstract]   [Full Text] [Related]  

  • 53. Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?
    Chade AR; Stewart N
    J Am Soc Hypertens; 2013; 7(2):180-90. PubMed ID: 23428409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial comment.
    Wijkstra H; de la Rosette JJ
    Urology; 2009 Sep; 74(3):681-2; author reply 682. PubMed ID: 19716926
    [No Abstract]   [Full Text] [Related]  

  • 55. The renal vascular response to vasodepressor sympathomimetics.
    SPENCER MP
    J Pharmacol Exp Ther; 1956 Feb; 116(2):237-44. PubMed ID: 13296039
    [No Abstract]   [Full Text] [Related]  

  • 56. The use of video imaging techniques to study ultrafiltration and blood flow in the normal and diseased kidney.
    Savin VJ
    Int Rev Exp Pathol; 1988; 30():321-55. PubMed ID: 3061962
    [No Abstract]   [Full Text] [Related]  

  • 57. [A neurovascular unit as a point of action of some vasoactive and neuroprotective drugs].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9):103-7. PubMed ID: 23373082
    [No Abstract]   [Full Text] [Related]  

  • 58. Increased platelet adhesiveness in hypertensive cardiovascular disease.
    Poplawski A; Skorulska M; Niewiarowski S
    J Atheroscler Res; 1968; 8(4):721-3. PubMed ID: 5679953
    [No Abstract]   [Full Text] [Related]  

  • 59. Drug-induced changes in blood pressure and in blood sodium as measured by glass electrode.
    FRIEDMAN SM; JAMIESON JD; HINKE JA; FRIEDMAN CL
    Am J Physiol; 1959 May; 196(5):1049-52. PubMed ID: 13649929
    [No Abstract]   [Full Text] [Related]  

  • 60. Pressor substances in kidneys of renal hypertensive rats with and without adrenals.
    GROSS F; LICHTLEN P
    Proc Soc Exp Biol Med; 1958 Jun; 98(2):341-5. PubMed ID: 13554639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.